α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and the formation of aggregates (Lewy bodies) in neurons. alpha-Synuclein is the major protein in Lewy bodies and rare mutations in alpha-synuclein cause early-onset PD. Consequently, alpha-synuclein is implicated in the pathogenesis of PD. Here, we have investigated the degradation pathways of alpha-synuclein, using a stable inducible PC12 cell model, where the expression of exogenous human wild-type, A30P, or A53T alpha-synuclein can be switched on and off. We have used a panel of inhibitors/stimulators of autophagy and proteasome function and followed alpha-synuclein degradation in these cells. We found that not only is alpha-synuclein degraded by the proteasome, but it is also degraded by autophagy. A role for autophagy was further supported by the presence of alpha-synuclein in organelles with the ultrastructural features of autophagic vesicles. Since rapamycin, a stimulator of autophagy, increased clearance of alpha-synuclein, it merits consideration as a potential therapeutic for Parkinsons disease, as it is designed for chronic use in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, mutant forms of synuclein and oligomers are dependent on the autophagy–lysosome pathway for their clearance4–6.”
From Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice (2018) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies suggest that α-synuclein is degraded by macroautophagy, chaperone-mediated autophagy, and the proteasome20–23.”
From Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration (2020) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Macroautophagy is a key pathway for the clearance of aggregate-prone cytosolic proteins.”
From Lithium induces autophagy by inhibiting inositol monophosphatase (2005) · cites this paper as Webb et al., 2003
In the citing paper
“Early evidence suggested roles for CMA and macroautophagy in degrading SNCA/α‐synuclein (Webb et al, 2003; Cuervo et al, 2004).”
From Autophagy in major human diseases (2021) · cites this paper as Webb et al, 2003
In the citing paper
“We previously showed that EGFP-HDQ74 is cleared by autophagy.”
From Lithium induces autophagy by inhibiting inositol monophosphatase (2005) · cites this paper as Webb et al., 2003
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Greene, L. A., & Tischler, A. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.7.2424 · Cited by 5,553
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
A Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Research works printed but not linked: 2
- Furlong, R. A., Narain, Y., Rankin, J., Wyttenbach, A., and Rubinsztein, D. C. (2000) Biochem. J. 346, 577-581 · DOI · Paper page
- Biederbick, A., Kern, H. F., and Elsasser, H. P. (1995) Eur. J. Cell Biol. 66, 3-14
Cited by
Items 201–300 of 1,001
Huntington’s disease: degradation of mutant huntingtin by autophagy
Sarkar, S., & Rubinsztein, D. C. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06562.x · Cited by 209
Self-citationThe role of free radicals in the aging brain and Parkinson’s Disease: Convergence and parallelism
Kumar, H., Lim, H.-W., More, S. V., Kim, B.-W., Koppula, S., Kim, I. S., & Choi, D.-K. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130810478 · Cited by 212
“The ubiquitylation of α-synuclein within LBs suggests a connection with proteasomes, and α-synuclein is a known substrate of chaperone-mediated autophagy involving lysosomes [114–116].”
BackgroundAutophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment
Poehler, A.-M., Xiang, W., Spitzer, P., May, V. E. L., Meixner, H., Rockenstein, E., Chutna, O., Outeiro, T. F., Winkler, J., Masliah, E., et al. (2014) · Autophagy · doi:10.4161/auto.36436 · Cited by 212
Microglia as modulators of exosomal alpha-synuclein transmission
Xia, Y., Zhang, G., Han, C., Ma, K., Guo, X., Wan, F., Kou, L., Yin, S., Liu, L., Huang, J., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1404-9 · Cited by 206
Autophagic Stress in Neuronal Injury and Disease
Chu, C. T. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000229233.75253.be · Cited by 211
“>-Synuclein, which forms Lewy body and neurite aggregates in PD, is also degraded by autophagic mechanisms (83, 84), particularly in the presence of pathogenic mutations that interfere with normal chaperonemediated degradation of this protein (64, 85).”
Ho, P. W.-L., Leung, C.-T., Liu, H., Pang, S. Y.-Y., Lam, C. S.-C., Xian, J., Li, L., Kung, M. H.-W., Ramsden, D. B., & Ho, S.-L. (2020) · Autophagy · doi:10.1080/15548627.2019.1603545 · Cited by 207
“‘VKKDQ’) for CMA-specific degradation, it is possible that this protein may be degraded via alternative non-CMA pathways [71].”
BackgroundProteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress
Höhn, A., Tramutola, A., & Cascella, R. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5497046 · Cited by 192
Autophagic failure promotes the exocytosis and intercellular transfer of α-synuclein
Lee, H.-J., Cho, E.-D., Lee, K. W., Kim, J.-H., Cho, S.-G., & Lee, S.-J. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.45 · Cited by 201
The ubiquitin-proteasome system and autophagy: Coordinated and independent activities
Cohen-Kaplan, V., Livneh, I., Avni, N., Cohen-Rosenzweig, C., & Ciechanover, A. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.07.019 · Cited by 196
Therapeutic targeting of autophagy in neurodegenerative and infectious diseases
Rubinsztein, D. C., Bento, C. F., & Deretic, V. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150956 · Cited by 202
“Consistent with the model above, the aggregate-prone forms of such proteins, including tau (Berger et al., 2006), -synuclein (Webb et al., 2003; Spencer et al., 2009), mutant huntingtin (Ravikumar et al., 2002), and mutant ataxin 3 (Berger et al., 2006) appear to have a higher dependency on…”
BackgroundSelf-citationBourdenx, M., Koulakiotis, N. S., Sanoudou, D., Bezard, E., Dehay, B., & Tsarbopoulos, A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.003 · Cited by 185
“Several studies clearly established that a-syn is degraded by both ubiquitin–proteasome system (UPS) and autophagy-lysosome pathways (ALP) (Bennett et al., 1999; Cuervo et al., 2004; Webb et al., 2003).”
BackgroundProteasomes Activate Aggresome Disassembly and Clearance by Producing Unanchored Ubiquitin Chains
Hao, R., Nanduri, P., Rao, Y., Panichelli, R. S., Ito, A., Yoshida, M., & Yao, T.-P. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.016 · Cited by 197
“Molecu proteins resistant to proteasomal degradation are processed by autophagy, where they are sequestered by autophagosomes and delivered to lysosomes for clearance (Holmberg et al., 2004; Venkatraman et al., 2004; Webb et al., 2003).”
Sekiguchi, A., Kanno, H., Ozawa, H., Yamaya, S., & Itoi, E. (2012) · Journal of Neurotrauma · doi:10.1089/neu.2011.1919 · Cited by 200
“In such neurodegenerative diseases, induction of autophagy by rapamycin enhances the clearance of a wide range of aggregation-prone proteins and reduces their toxicity (Berger et al., 2006; Webb et al., 2003).”
Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications
Banerjee, R., Beal, M. F., & Thomas, B. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.09.001 · Cited by 199
Rott, R., Szargel, R., Shani, V., Hamza, H., Savyon, M., Abd Elghani, F., Bandopadhyay, R., & Engelender, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704351114 · Cited by 188
The role of α-synuclein in neurodegenerative diseases
Bennett, M. C. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.010 · Cited by 197
The Autophagy Lysosomal Pathway and Neurodegeneration
Finkbeiner, S. (2020) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033993 · Cited by 196
“Although the ALP plays an important role in the turnover of proteins, other pathways including the unfolded protein response (UPR) and the ubiquitin proteasome system (UPS) are also critical (Webb et al. 2003; Keller et al. 2004; Kabuta et al. 2006; Wang et al. 2009, 2010a; Benbrook and Long 2012; Wang and Mandelkow 2…”
BackgroundAzeredo da Silveira, S., Schneider, B. L., Cifuentes-Diaz, C., Sage, D., Abbas-Terki, T., Iwatsubo, T., Unser, M., & Aebischer, P. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn417 · Cited by 190
“autophagy [50-53], and autophagic lysosomal impairment is known to participate in the amyloidogenic aggregation of -syn [51, 54-56].”
BackgroundThe Parkinson’s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway
Bento, C. F., Ashkenazi, A., Jimenez-Sanchez, M., & Rubinsztein, D. C. (2016) · Nature Communications · doi:10.1038/ncomms11803 · Cited by 193
Self-citationAutophagy for tissue homeostasis and neuroprotection
Mariño, G., Madeo, F., & Kroemer, G. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.10.001 · Cited by 195
“In fact, it has been reported that treatment with rapamycin or its analogues, the ‘rapalogues’, which all enhance autophagosome formation through the inhibition of mTORC1, protects against the toxicity of a wide variety of aggregate-prone proteins in vitro (including those associated with HD, SCAs, PD, or FTD) and sub…”
BackgroundSuzuki, M., Shinohara, Y., Ohsaki, Y., & Fujimoto, T. (2011) · Microscopy · doi:10.1093/jmicro/dfr016 · Cited by 195
Autophagy in Neuroprotection and Neurodegeneration: A Question of Balance
Cherra 3rd, S. J., & Chu, C. T. (2008) · Future Neurology · doi:10.2217/14796708.3.3.309 · Cited by 192
“This concept arose from data showing that many neurodegenerative disease mutations result in aggregateprone proteins, and that induction of autophagy can reduce the levels of protein aggregates in multiple systems [21–24].”
BackgroundHeiseke, A., Aguib, Y., Riemer, C., Baier, M., & Schätzl, H. M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05906.x · Cited by 183
“(2009) 109, 25–34 25 causing Huntington¢s and Parkinson’s disease, respectively, can be mediated by autophagy (Ravikumar et al. 2002; Webb et al. 2003).”
BackgroundAmyloid assembly and disassembly
Chuang, E., Hori, A. M., Hesketh, C. D., & Shorter, J. (2018) · Journal of Cell Science · doi:10.1242/jcs.189928 · Cited by 183
“, 2014), αSyn (Webb et al., 2003), polyglutamine (Yamamoto et al.”
BackgroundAutophagy in disease: a double-edged sword with therapeutic potential
Martinet, W., Agostinis, P., Vanhoecke, B., Dewaele, M., & de Meyer, G. R. Y. (2009) · Clinical Science · doi:10.1042/cs20080508 · Cited by 186
Mitochondrial translocation of α-synuclein is promoted by intracellular acidification
Cole, N. B., DiEuliis, D., Leo, P., Mitchell, D. C., & Nussbaum, R. L. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.03.012 · Cited by 185
“As α-synuclein is normally degraded, in part, by autophagy [68], defective mitochondrial turnover may also result in the accumulation of mitochondrially-bound synuclein, with subsequent synuclein aggregation/fibrillization leading ultimately to Lewy body formation.”
BackgroundLi, W., Lesuisse, C., Xu, Y., Troncoso, J. C., Price, D. L., & Lee, M. K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1370-04.2004 · Cited by 178
“…inhibition does not affect the total -Syn levels but slows the clearance of -Syn oligomers in cells (Lee et al., 2004); however, proteasomal activity and autophagy have been implicated in the degradation of epitope-tagged -Syn variants in a neural cell line (PC12 cells) (Webb et al., 2003).”
BackgroundResultInfluentialAutophagy protects neuron from Aβ-induced cytotoxicity
Hung, S.-Y., Huang, W.-P., Liou, H.-C., & Fu, W.-M. (2009) · Autophagy · doi:10.4161/auto.5.4.8096 · Cited by 181
How is alpha‐synuclein cleared from the cell?
Stefanis, L., Emmanouilidou, E., Pantazopoulou, M., Kirik, D., Vekrellis, K., & Tofaris, G. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14704 · Cited by 175
“Webb et al. (2003), used an inducible system in PC12 cells to overexpress Wild Type (WT) or mutant A53T or A30P human a-Syn, and pharmacological tools to inhibit the proteasome, the lysosome, more generally with bafilomycin, or macroautophagy specifically, using 3-Methyladenine (3-MA).”
BackgroundMethodResultInfluentialMechanisms tailoring the expression of heat shock proteins to proteostasis challenges
Alagar Boopathy, L. R., Jacob-Tomas, S., Alecki, C., & Vera, M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101796 · Cited by 174
Rott, R., Szargel, R., Haskin, J., Shani, V., Shainskaya, A., Manov, I., Liani, E., Avraham, E., & Engelender, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m704809200 · Cited by 174
Autophagy and Neuronal Cell Death in Neurological Disorders
Nixon, R. A., & Yang, D.-S. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008839 · Cited by 181
“…cause similar CMA dysfunction suggesting that this form of a-synuclein toxicity applies to sporadic as well as familial forms of PD (Xilouri et al. 2009). a-Synuclein is also a substrate for macroautophagy (Webb et al. 2003), which may be recruited as a compensatory mechanism when CMA is impaired.”
BackgroundAll-you-can-eat: autophagy in neurodegeneration and neuroprotection
Jaeger, P. A., & Wyss-Coray, T. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-16 · Cited by 175
“Pharmacological inhibition of either pathway leads to increased intracellular α-synuclein levels [218].”
Genes, proteins, and neurotoxins involved in Parkinson’s disease
Halbach, O. V. B. U., Schober, A., & Krieglstein, K. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.002 · Cited by 181
“A role for autophagy is supported by the presence of -synuclein in organelles with the ultrastructural features of autophagic vesicles (Webb et al., 2003), but to date it is not clear to which extent autophagy plays a role in the degradation of misfolded -synuclein.”
BackgroundLysosomal Dysfunction and α‐Synuclein Aggregation in Parkinson's Disease: Diagnostic Links
Moors, T., Paciotti, S., Chiasserini, D., Calabresi, P., Parnetti, L., Beccari, T., & van de Berg, W. D. J. (2016) · Movement Disorders · doi:10.1002/mds.26562 · Cited by 173
α-Synuclein fate is determined by USP9X-regulated monoubiquitination
Rott, R., Szargel, R., Haskin, J., Bandopadhyay, R., Lees, A. J., Shani, V., & Engelender, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105725108 · Cited by 174
“While autophagy inhibitors, such as 3-MA, promote the accumulation of α-synuclein (10, 16), activators of this pathway, such as rapamycin, decrease α-synuclein levels (16).”
BackgroundUbiquitination of -synuclein by Siah-1 promotes -synuclein aggregation and apoptotic cell death
Lee, J. T., Wheeler, T. C., Li, L., & Chin, L.-S. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm363 · Cited by 170
Cell systems and the toxic mechanism(s) of α-synuclein
Cookson, M. R., & van der Brug, M. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.022 · Cited by 173
“In cells, most α-synuclein is not degraded by the proteasome, but rather by lysosomal enzymes (Paxinou et al., 2001; Webb et al., 2003).”
BackgroundConstitutive Upregulation of Chaperone-Mediated Autophagy in Huntington's Disease
Koga, H., Martinez-Vicente, M., Arias, E., Kaushik, S., Sulzer, D., & Cuervo, A. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3219-11.2011 · Cited by 174
“Protein aggregates can be removed by macroautophagy, one of the lysosomal pathways that contribute to the degradation of cytosolic material in lysosomes (Webb et al., 2003; Fornai et al., 2008; Wang et al., 2009).”
BackgroundTang, G., Yue, Z., Talloczy, Z., Hagemann, T., Cho, W., Messing, A., Sulzer, D. L., & Goldman, J. E. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn042 · Cited by 172
Gründemann, J., Schlaudraff, F., Haeckel, O., & Liss, B. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn084 · Cited by 174
Protein aggregation: From background to inhibition strategies
Alam, P., Siddiqi, K., Chturvedi, S. K., & Khan, R. H. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.05.048 · Cited by 166
Autophagy induction by trehalose: Molecular mechanisms and therapeutic impacts
Hosseinpour‐Moghaddam, K., Caraglia, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26583 · Cited by 168
“In laboratory experiments, autophagy inducers such as rapamycin help the elimination of α-Syn (Webb et al., 2003), whilst autophagy inhibitors augment its accumulation (Rott et al., 2008).”
BackgroundRapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5
Diaz-Griffero, F., Li, X., Javanbakht, H., Song, B., Welikala, S., Stremlau, M., & Sodroski, J. (2006) · Virology · doi:10.1016/j.virol.2005.12.040 · Cited by 171
“Cytoplasmic inclusion bodies associated with neurodegenerative protein aggregates have been shown to be susceptible to autophagic degradation (Ravikumar et al., 2002; Webb et al., 2003; Cuervo et al., 2004; Iwata et al., 2005).”
BackgroundThe Salmonella Deubiquitinase SseL Inhibits Selective Autophagy of Cytosolic Aggregates
Mesquita, F. S., Thomas, M., Sachse, M., Santos, A. J. M., Figueira, R., & Holden, D. W. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002743 · Cited by 168
Perfeito, R., Cunha-Oliveira, T., & Rego, A. C. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.05.042 · Cited by 164
“[167] Webb J.”
mTOR/AMPK signaling in the brain: Cell metabolism, proteostasis and survival
Garza-Lombó, C., Schroder, A., Reyes-Reyes, E. M., & Franco, R. (2018) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2018.05.002 · Cited by 158
Constitutive autophagy: vital role in clearance of unfavorable proteins in neurons
Komatsu, M., Ueno, T., Waguri, S., Uchiyama, Y., Kominami, E., & Tanaka, K. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402120 · Cited by 160
Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway
Inoue, K., Rispoli, J., Kaphzan, H., Klann, E., Chen, E. I., Kim, J., Komatsu, M., & Abeliovich, A. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-48 · Cited by 168
Webb, J. L., Ravikumar, B., & Rubinsztein, D. C. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.02.003 · Cited by 167
Self-citationAutophagy in tumor suppression and cancer therapy
Kung, C.-P., Budina, A., Balaburski, G., Bergenstock, M. K., & Murphy, M. (2011) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v21.i1.50 · Cited by 166
Caffeine and Parkinson’s Disease: Multiple Benefits and Emerging Mechanisms
Ren, X., & Chen, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.602697 · Cited by 180
“Second, abnormally aggregated α-Syn inclusions are mainly degraded by autophagy (Webb et al., 2003) and defects or deficiency of autophagy can lead to accumulation of intracellular misfolded amyloid α-Syn aggregates, thus causally linking autophagy to PD pathological process (Xilouri et al.”
BackgroundThe Ubiquitin-Proteasome System in Neurodegeneration
McKinnon, C., & Tabrizi, S. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5802 · Cited by 165
“In vitro studies have provided conflicting accounts on the relative importance of the UPS and autophagy to the degradation of mutant forms of a -synuclein (191, 197).”
Biological links between traumatic brain injury and Parkinson’s disease
Delic, V., Beck, K. D., Pang, K. C. H., & Citron, B. A. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00924-7 · Cited by 165
The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders
Vidoni, C., Follo, C., Savino, M., Melone, M. A. B., & Isidoro, C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21394 · Cited by 164
Small molecule enhancers of autophagy for neurodegenerative diseases
Sarkar, S., & Rubinsztein, D. C. (2008) · Molecular BioSystems · doi:10.1039/b804606a · Cited by 163
Self-citationα-Synuclein Suppression by Targeted Small Interfering RNA in the Primate Substantia Nigra
McCormack, A. L., Mak, S. K., Henderson, J. M., Bumcrot, D., Farrer, M. J., & Di Monte, D. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012122 · Cited by 158
Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy
Fussi, N., Höllerhage, M., Chakroun, T., Nykänen, N.-P., Rösler, T. W., Koeglsperger, T., Wurst, W., Behrends, C., & Höglinger, G. U. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0816-2 · Cited by 161
Song, J.-X., Lu, J.-H., Liu, L.-F., Chen, L.-L., Durairajan, S. S. K., Yue, Z., Zhang, H.-Q., & Li, M. (2014) · Autophagy · doi:10.4161/auto.26751 · Cited by 160
Autophagy-mediated clearance of aggresomes is not a universal phenomenon
Wong, E. S. P., Tan, J. M. M., Soong, W.-E., Hussein, K., Nukina, N., Dawson, V. L., Dawson, T. M., Cuervo, A. M., & Lim, K.-L. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn157 · Cited by 159
Role of the ubiquitin proteasome system in Parkinson's disease
Lim, K.-L., & Tan, J. M. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s13 · Cited by 151
Chen, Y., Yang, L., Feng, C., & Wen, L.-P. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.018 · Cited by 159
Autophagy, a guardian against neurodegeneration
García-Arencibia, M., Hochfeld, W. E., Toh, P. P. C., & Rubinsztein, D. C. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2010.02.008 · Cited by 158
Self-citationBendotti, C., Marino, M., Cheroni, C., Fontana, E., Crippa, V., Poletti, A., & Biasi, S. D. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.10.001 · Cited by 187
Underwood, B. R., Imarisio, S., Fleming, A., Rose, C., Krishna, G., Heard, P., Quick, M., Korolchuk, V. I., Renna, M., Sarkar, S., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq253 · Cited by 155
“We found that NAC was able to impair the clearance of an autophagy substrate, haemagglutinin (HA)-tagged mutant A53T a-synuclein, a soluble protein that causes a form of familial PD (22).”
BackgroundSelf-citationCongenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism
Ebrahimi-Fakhari, D., Saffari, A., Wahlster, L., Lu, J., Byrne, S., Hoffmann, G. F., Jungbluth, H., & Sahin, M. (2016) · Brain · doi:10.1093/brain/awv371 · Cited by 158
α-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease
Mullin, S., & Schapira, A. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8394-x · Cited by 146
Marongiu, R., Spencer, B., Crews, L., Adame, A., Patrick, C., Trejo, M., Dallapiccola, B., Valente, E. M., & Masliah, E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05932.x · Cited by 156
Floto, R. A., Sarkar, S., Perlstein, E. O., Kampmann, B., Schreiber, S. L., & Rubinsztein, D. C. (2007) · Autophagy · doi:10.4161/auto.4898 · Cited by 158
Self-citationCalpain is required for macroautophagy in mammalian cells
Demarchi, F., Bertoli, C., Copetti, T., Tanida, I., Brancolini, C., Eskelinen, E.-L., & Schneider, C. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200601024 · Cited by 156
“Autophagy is protective during the initial stages of neurodegeneration (Webb et al., 2003; Ravikumar et al., 2004), whereas it becomes deleterious at later stages (Yue et al., 2002).”
BackgroundHouck, S. A., Ren, H. Y., Madden, V. J., Bonner, J. N., Conlin, M. P., Janovick, J. A., Conn, P. M., & Cyr, D. M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.02.025 · Cited by 147
Haj‐Yahya, M., Fauvet, B., Herman-Bachinsky, Y., Hejjaoui, M., Bavikar, S. N., Karthikeyan, S. V., Ciechanover, A. J., Lashuel, H. A., & Brik, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315654110 · Cited by 163
Dysfunctions of neuronal and glial intermediate filaments in disease
Liem, R. K. H., & Messing, A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38003 · Cited by 149
α-synuclein phosphorylation and truncation are normal events in the adult human brain
Muntané, G., Ferrer, I., & Martínez‐Vicente, M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.10.042 · Cited by 167
Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond
Shachar, T., Bianco, C. L., Recchia, A., Wiessner, C., Raas‐Rothschild, A., & Futerman, A. H. (2011) · Movement Disorders · doi:10.1002/mds.23774 · Cited by 150
“Differentiated cells such as neurons are more susceptible to autophagy blockage because the accumulation of aggregated protein cannot be eliminated or lowered by cell division.(75,107) Autophagy impairment is seen in a number of LSDs(32,108) as well as in PD.”
BackgroundDysfunction of Cellular Proteostasis in Parkinson’s Disease
Lehtonen, Š., Sonninen, T.-M., Wojciechowski, S., Goldsteins, G., & Koistinaho, J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00457 · Cited by 147
“While α-SYN can be cleared by UPP, the main pathway for its degradation appears to be lysosomal (Webb et al., 2003; Vogiatzi et al., 2008). α-SYN can be degraded by both macroautophagy and CMA, but the structure and mutations may change the final path of degradation.”
BackgroundNeuronal autophagy and mitophagy in Parkinson's disease
Lizama, B. N., & Chu, C. T. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100972 · Cited by 160
Disruption of Protein Quality Control in Parkinson's Disease
Cook, C., Stetler, C., & Petrucelli, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009423 · Cited by 147
“This view is consistent with the demonstration that aggregates of mutant a-synuclein can be cleared by macroautophagy (Webb et al. 2003), and activation of the latter under this condition is likely a result of the inhibition that mutant and modified asynuclein exert on UPS and CMA activity (Iwata et al.”
BackgroundResultThe Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders
Velayati, A., Yu, W. H., & Sidransky, E. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0102-x · Cited by 145
“In addition to the lysosome, the autophagic vacuole also has been determined to be a compartment requisite for αsynuclein clearance [69, 70] through the engulfment of the cytoplasmic or vesicular form of α-synuclein and its delivery to the lysosome for final degradation.”
BackgroundC. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease
Harrington, A. J., Hamamichi, S., Caldwell, G. A., & Caldwell, K. A. (2010) · Developmental Dynamics · doi:10.1002/dvdy.22231 · Cited by 174
“Most notably, recent findings indicate that the bulk of misfolded and aggregated proteins, including a-syn, are degraded by lysosomes by means of macroautophagy and chaperone-mediated autophagy (Webb et al., 2003; Cuervo et al., 2004; Fig.”
BackgroundInvolvement of ROS in Curcumin-induced Autophagic Cell Death
Lee, Y. J., Kim, N., Suh, Y., & Lee, C. (2011) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2011.15.1.1 · Cited by 148
“It has been reported that autophagy plays a crucial role in many diseases such as cancer, infectious diseases, and neurodegenerative disorders [4-7].”
BackgroundGenetic and Chemical Activation of TFEB Mediates Clearance of Aggregated α-Synuclein
Kilpatrick, K., Zeng, Y., Hancock, T., & Segatori, L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120819 · Cited by 145
“mediating the degradation of long-lived proteins by the lysosome [8], autophagy also plays a key role in promoting clearance of misfolded and aggregated α-syn [9,10].”
BackgroundTau-Based Treatment Strategies in Neurodegenerative Diseases
Schneider, A., & Mandelkow�, E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.006 · Cited by 160
“tingtin and -synuclein aggregates, and also for tau.(168,169) Rapamycin inhibits mTOR (mammalian target of rapamycin), thereby promoting autophagy.”
Ahmed, I., Liang, Y., Schools, S., Dawson, V. L., Dawson, T. M., & Savitt, J. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0209-12.2012 · Cited by 144
“Prior studies have shown that α-synuclein is degraded by both macroautophagy and chaperone mediated autophagy (CMA) (Webb et al., 2003; Cuervo et al., 2004; Vogiatzi et al., 2008).”
BackgroundMalkus, K. A., Tsika, E., & Ischiropoulos, H. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-24 · Cited by 142
“Stimulation of autophagy has been accomplished either by rapamycin, which inhibits the negative regulator of autophapgy mammalian target of rapamycin (mTOR), or by several mTOR independent compounds including lithium, trehalose, and small molecules identified in a screen [29-35].”
BackgroundUpregulated autophagy protects cardiomyocytes from oxidative stress-induced toxicity
Dutta, D., Xu, J., Kim, J.-S., Dunn Jr., W. A., & Leeuwenburgh, C. (2013) · Autophagy · doi:10.4161/auto.22971 · Cited by 141
Interaction Between the Glymphatic System and α-Synuclein in Parkinson’s Disease
Zhang, Y., Zhang, C., He, X.-Z., Li, Z., Meng, J., Mao, R.-T., Li, X., Xue, R., Gui, Q., Zhang, G., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03212-2 · Cited by 153
“Previous studies reported that α-syn was degraded through various intracellular clearance mechanisms such as ubiquitin–proteasome system and autophagy–lysosomal pathway [14, 15].”
BackgroundProtein degradation, aggregation, and misfolding
Cuervo, A. M., Wong, E. S. P., & Martinez‐Vicente, M. (2010) · Movement Disorders · doi:10.1002/mds.22718 · Cited by 138
“Furthermore, modification of a-synuclein by cytosolic dopamine has an effect similar to that described for the mutations, because it also blocks CMA.”
BackgroundInfluential“LRRK2: Autophagy and Lysosomal Activity”
Madureira, M., Connor-Robson, N., & Wade-Martins, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00498 · Cited by 137
SH-SY5Y Cell Line In Vitro Models for Parkinson Disease Research—Old Practice for New Trends
Ioghen, O. C., Ceafalan, L. C., & Popescu, B. O. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2201020 · Cited by 160
“In the neuronal cells, the autophagy-lysosome pathway is an important route of degrading the pathological protein alpha-synuclein, along with the ubiquitin-proteasome system [17].”
BackgroundAlpha-synuclein aggregation involves a bafilomycin A1-sensitive autophagy pathway
Klucken, J., Poehler, A.-M., Ebrahimi-Fakhari, D., Schneider, J., Nuber, S., Rockenstein, E., Schlötzer-Schrehardt, U., Hyman, B. T., McLean, P. J., Masliah, E., et al. (2012) · Autophagy · doi:10.4161/auto.19371 · Cited by 137
TOR-mediated autophagy regulates cell death in Drosophila neurodegenerative disease
Wang, T., Lao, U., & Edgar, B. A. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200904090 · Cited by 134
“Autophagy has been shown to be important in the clearance of cellular aggregates in several neurodegenerative disease models (Ravikumar et al., 2002; Webb et al., 2003; Iwata et al., 2005).”
BackgroundAutophagy impairment in Parkinson’s disease
Karabiyik, C., Lee, M. J., & Rubinsztein, D. C. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170023 · Cited by 140
“There is compelling evidence suggesting that impaired trafficking to the lysosome is a common mechanism underlying PD pathogenesis and that the aggregate-prone α-syn is an autophagy substrate (21,75).”
BackgroundResultSelf-citationUddin, M. S., Mamun, A. A., Labu, Z. K., Hidalgo‐Lanussa, O., Barreto, G. E., & Ashraf, G. M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27588 · Cited by 141
He, Q., Koprich, J. B., Wang, Y., Yu, W., Xiao, B., Brotchie, J. M., & Wang, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9173-7 · Cited by 147
Cell “Self‐Eating” (Autophagy) Mechanism in Alzheimer's Disease
Funderburk, S. F., Marcellino, B. K., & Yue, Z. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20161 · Cited by 139
Liu, W., Vives-Bauza, C., Acín-Peréz-, R., Yamamoto, A., Tan, Y., Li, Y., Magrané, J., Stavarache, M. A., Shaffer, S., Chang, S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004597 · Cited by 135
“a-synuclein is known to be a target of proteasome degradation in the cytosol [53,54].”
BackgroundAskanas, V., Engel, W. K., & Nogalska, A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00290.x · Cited by 141
“a-Syn is degraded by both the 26S proteasome and by lysosomal autophagy (68, 113).”
BackgroundBłasiak, J., Pawłowska, E., Szczepańska, J., & Kaarniranta, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010210 · Cited by 150
“α-synuclein can be degraded at the same time by UPS and autophagy [116].”
BackgroundThe Emerging Role of the Lysosome in Parkinson’s Disease
Navarro-Romero, A., Montpeyó, M., & Martinez-Vicente, M. (2020) · Cells · doi:10.3390/cells9112399 · Cited by 135
“In addition, and like many other cytosolic proteins, α-synuclein can also be degraded simultaneously by the ubiquitin-proteasome system (UPS), although it is not the main mechanism, as inhibition of proteasome function does not result in abnormal accumulation of α-synuclein [59].”
Background
Metadata
- Authors
- Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C.
- Affiliations
- Addenbrooke's Hospital (GB)
- University of Cambridge (GB)
- Corresponding author
- Rubinsztein, David C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 278
- Issue
- 27
- Pages
- 25009-25013
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2157535220
- Cited by
- 1,429
- References
- 37
- Citations by year
- 2026: 36 · 2025: 41 · 2024: 76 · 2023: 50 · 2022: 68 · 2021: 71 · 2020: 83 · 2019: 85 · 2018: 77 · 2017: 62 · 2016: 65 · 2015: 65 · 2014: 75 · 2013: 79 · 2012: 95
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6305 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Parkinson's UK
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- alpha-synuclein, Parkinson's disease, autophagy, proteasome, protein degradation, Lewy bodies, A30P mutation, A53T mutation, PC12 cells, rapamycin, autophagic vesicles, dopaminergic neurons
- MeSH terms
- Animals, Antibiotics, Antineoplastic, Autophagy, Cysteine Endopeptidases, Humans, Multienzyme Complexes, Nerve Tissue Proteins, PC12 Cells, Sirolimus, Proteasome Endopeptidase Complex, Rats, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.